Division of Laboratory Genetics and Genomics.
Division of Hematopathology, Mayo Clinic, Rochester, MN.
Am J Surg Pathol. 2021 Nov 1;45(11):1534-1540. doi: 10.1097/PAS.0000000000001732.
The presence of increased multinucleated megakaryocytes (aka osteoclast-like) is considered a dysplastic feature in myelodysplastic syndrome; however, its clinical significance in isolation is uncertain. Herein, we report the clinicopathologic and genetic features of 18 such cases of 40,539 bone marrow biopsies spanning 10 years. All 18 patients had ≥25% multinucleated megakaryocytes in otherwise normal bone marrow biopsies, which were evaluated for plasma cell neoplasms (n=9), lymphoma (n=4), or anemia/neutropenia (n=5). None of the 17 patients tested showed acquired cytogenetic abnormalities. Sixteen patients underwent targeted gene panel next-generation sequencing: 9 patients had no pathogenic mutations; 3 harbored a single pathogenic mutation with variant allele frequencies of 7.5%, 7.6%, and 10.7%, likely representing clonal hematopoiesis of indeterminate potential; 1 had 2 pathogenic mutations, 1 of which had a variant allele frequency >20%. Fourteen of 18 patients had a follow-up period >6 months (median: 36.5 mo, range: 7 to 110 mo) and no patients developed a new-onset cytopenia, a progressive cytopenia, or a myeloid neoplasm. The patient with 2 mutations had persistent anemia, worrisome for an emerging MDS. However, given the absence of thrombocytopenia, increased multinucleated megakaryocytes in this patient could be an unrelated incidental finding. Our study indicates that increased multinucleated megakaryocytes as an isolated finding is a rare phenomenon, and this sole morphologic finding is not diagnostic of myelodysplastic syndrome. Diagnostic approaches in the presence of increased multinucleated megakaryocytes are proposed based on different clinical and pathologic scenarios.
骨髓活检中存在增多的多核巨核细胞(又名破骨细胞样)被认为是骨髓增生异常综合征的一种发育异常特征;然而,其孤立存在的临床意义尚不确定。在此,我们报告了 10 年间 40539 例骨髓活检中 18 例这种病例的临床病理和遗传学特征。所有 18 例患者的骨髓活检中均存在≥25%的多核巨核细胞,而这些患者的骨髓活检评估结果为浆细胞瘤(n=9)、淋巴瘤(n=4)或贫血/中性粒细胞减少症(n=5)。17 例患者中没有任何患者检测到获得性细胞遗传学异常。16 例患者接受了靶向基因panel 下一代测序:9 例患者无致病性突变;3 例患者存在单个致病性突变,其变异等位基因频率分别为 7.5%、7.6%和 10.7%,可能代表不确定的潜在克隆性造血;1 例患者存在 2 个致病性突变,其中 1 个的变异等位基因频率>20%。18 例患者中有 14 例的随访时间>6 个月(中位数:36.5 个月,范围:7 至 110 个月),没有患者出现新发血细胞减少症、进行性血细胞减少症或髓系肿瘤。有 2 个突变的患者持续存在贫血,令人担忧的是出现了 MDS。然而,鉴于该患者没有血小板减少症,该患者骨髓中增多的多核巨核细胞可能是无关的偶发发现。我们的研究表明,孤立性多核巨核细胞增多是一种罕见现象,这种单一的形态学发现不能诊断为骨髓增生异常综合征。基于不同的临床和病理情况,提出了在存在多核巨核细胞增多时的诊断方法。